We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LGEN:LSELegal & General Group Plc Analysis

Data as of 2026-03-11 - not real-time

£258.50

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Legal & General trades at a trailing P/E of 64.6 versus an industry average of 17.3 and a price‑to‑book of 781, signalling clear overvaluation despite a forward P/E of 10.7 that hints at expected earnings upside. The stock offers an attractive 8.6% dividend yield, but a payout ratio of 484% raises serious concerns about sustainability, especially given negative operating cash flow and a debt‑to‑equity ratio exceeding 1,100. Technically, the price sits below the 20‑day SMA (266.1) and the MACD is in a bearish configuration, while volume is rising and the 30‑day volatility is near 25%, suggesting short‑term pressure with limited upside of about 3% before hitting resistance at 279.5.
The company’s revenue is growing at roughly 10% and free cash flow remains strong, yet the heavy leverage, regulatory exposure inherent to the insurance and asset‑management business, and the unsustainable dividend policy temper enthusiasm. Given the low beta (≈0.3) the stock is relatively insulated from market swings, but the combination of high valuation, leverage and dividend risk points to a cautious stance, favouring a hold in the near term and a measured buy on the medium horizon if earnings materialise, while maintaining vigilance on balance‑sheet health for the long run.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below short‑term SMA
  • Unsustainable dividend payout ratio
  • Limited near‑term upside versus resistance

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward P/E of 10.7 indicating earnings upside
  • Revenue growth near 10% and strong free cash flow
  • Increasing volume suggesting accumulating interest

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High leverage and debt‑to‑equity over 1,100
  • Regulatory and sector exposure in insurance/asset management
  • Persistently high valuation multiples

Key Metrics & Analysis

Financial Health

Revenue Growth9.70%
Profit Margin2.28%
P/E Ratio64.6
ROE9.49%
ROA0.10%
Debt/Equity1116.15
P/B Ratio781.0
Op. Cash Flow£-1488999936
Free Cash Flow£5.1B
Industry P/E17.3

Technical Analysis

TrendBullish
RSI45.0
Support£245.00
Resistance£279.50
MA 20£266.10
MA 50£264.90
MA 200£251.78
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair Value£1,654.00
Target Price£266.71
Upside/Downside3.17%
GradeOvervalued
TypeBlend
Dividend Yield8.60%

Risk Assessment

Beta0.32
Volatility24.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.